M&A Deal Summary

Covis Pharma Sàrl Acquires AMAG Pharmaceuticals

On November 16, 2020, Covis Pharma Sàrl acquired life science company AMAG Pharmaceuticals for 647M USD

Acquisition Highlights
  • This is Covis Pharma Sàrl’s 2nd transaction in the Life Science sector.
  • This is Covis Pharma Sàrl’s largest (disclosed) transaction.
  • This is Covis Pharma Sàrl’s 1st transaction in the United States.
  • This is Covis Pharma Sàrl’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2020-11-16
Target AMAG Pharmaceuticals
Sector Life Science
Buyer(s) Covis Pharma Sàrl
Deal Type Add-on Acquisition
Deal Value 647M USD
Advisor(s) Goldman Sachs (Financial)
Goodwin Procter (Legal)

Target

AMAG Pharmaceuticals

Waltham, Massachusetts, United States
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse. AMAG Pharmaceuticals was formed in 1981 and is based in Waltham, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Covis Pharma Sàrl

Luxembourg, Switzerland
Category Company
Sector Healthcare Services
DESCRIPTION

Covis Pharma is a specialty pharmaceutical company providing therapeutic solutions to patients. Covis markets a portfolio of U.S. prescription products through its U.S. sales and distribution affiliate, Covis Pharmaceuticals, Inc. which is headquartered in Cary, North Carolina.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-06 AstraZeneca - Alvesco Omnaris and Zetonna Business

London, United Kingdom

AstraZeneca Plc - Alvesco, Omnaris and Zetonna Business used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines.

Buy $350M
Mergr

Product

Company

Legal